



For more information:
Marta Campos Martínez
mcampos@rovi.es
Tel: +34 91 244 44 22

Rovi reaches agreement with Pérouse to terminate the distribution contract for implants for plastic surgery

Madrid – 13 January 2010 - Laboratorios Farmacéuticos Rovi (ROVI) and Pérouse Plastique (Pérouse), a manufacturer and distributor of implants for use in plastic and reconstructive surgery, have reached an agreement to terminate the distribution contract under the terms of which Pan Química Farmacéutica, a company owned by ROVI Group, has marketed the implants of Pérouse in Spain, since 22 January 2001. The agreement will be effective on 31 March 2010.

In 2007, Pérouse Plastique was acquired by Mentor Corporation, a leading supplier of medical products for the global aesthetic market.

The sales associated with this distribution contract are included under the business line of "aesthetic medicine products." ROVI reported sales in this line of 2.3 million euros in the 9 months to 30 September 2009 (related mainly to the distribution contract with Pérouse Plastique), which represented a 10% fall from the same period in the previous year. In this period of 2009, sales of "aesthetic medicine products" represented 2% of the total sales of ROVI.

ROVI continues to concentrate its efforts on its portfolio of specialty pharmaceuticals, which represented 60% of total group sales in the first nine months of 2009, and will continue to promote and market its prescription products, as the Emla® anaesthetic cream, in the plastic surgery field.

About ROVI

ROVI is a fully integrated, profitable Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 23 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, bemiparin. ROVI's research and development pipeline is focused primarily on addressing currently unmet medical needs by developing new LMWH-based products and expanding applications for its existing LMWH-based products. ROVI manufactures the active biological ingredient (bemiparin) for its principal proprietary product and product candidates and the injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. Additional information about ROVI is available on the company's website: www.rovi.es